| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ann M Mortimer, Eileen Joyce, Krishnapillai Balasubramaniam, Prasoon C Choudhary, Packeeruther T Salee. Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. Human psychopharmacology. vol 22. issue 7. 2008-01-17. PMID:17691076. |
treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. |
2008-01-17 |
2023-08-12 |
Not clear |
| Alain Dervaux, Joelle Cazal. Clozapine and amisulpride in refractory schizophrenia and alcohol dependence. Journal of clinical psychopharmacology. vol 27. issue 5. 2008-01-02. PMID:17873688. |
clozapine and amisulpride in refractory schizophrenia and alcohol dependence. |
2008-01-02 |
2023-08-12 |
Not clear |
| Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Seung-Hyun Lee, Jeong-Hoon Lee, Bo-Hyun Yoon, Su-Jin Yang, Michael Y Hwang, Jin-Sang Yoo. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 7. 2007-12-06. PMID:17692448. |
amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. |
2007-12-06 |
2023-08-12 |
Not clear |
| Divya Vohor. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Current opinion in investigational drugs (London, England : 2000). vol 8. issue 7. 2007-09-04. PMID:17659473. |
this review focuses on the comparative safety and efficacy profile of nine atypical antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine), which may ultimately affect the therapeutic options available for patients with schizophrenia. |
2007-09-04 |
2023-08-12 |
Not clear |
| Maria A Rettenbacher, Martina Hummer, Alex Hofer, Susanne Baumgartner, Christoph Ebenbichler, Monika Edlinger, Georg Kemmler, Monika Lechleitner, W Wolfgang Fleischhacke. Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. Journal of psychopharmacology (Oxford, England). vol 21. issue 4. 2007-08-24. PMID:17050656. |
we conducted a prospective, open study comparing body weight, parameters of insulin resistance in schizophrenia patients treated with either clozapine (n = 10) or amisulpride ( n = 12). |
2007-08-24 |
2023-08-12 |
Not clear |
| Matthias J Müller, Boris Regenbogen, Sebastian Härtter, Franz X Eich, Christoph Hiemk. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. Journal of psychiatric research. vol 41. issue 8. 2007-07-16. PMID:16324716. |
therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. |
2007-07-16 |
2023-08-12 |
Not clear |
| Joseph Peuskens, Marc De Hert, Ann Mortime. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. International clinical psychopharmacology. vol 22. issue 3. 2007-07-16. PMID:17414740. |
metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. |
2007-07-16 |
2023-08-12 |
Not clear |
| Joseph Peuskens, Marc De Hert, Ann Mortime. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. International clinical psychopharmacology. vol 22. issue 3. 2007-07-16. PMID:17414740. |
three hundred and seventy-seven adult patients with schizophrenia were randomized to either amisulpride (200-800 mg/day) or olanzapine (5-20 mg/day) for 6 months. |
2007-07-16 |
2023-08-12 |
Not clear |
| Yasin Genç, Ender Taner, Selcuk Candansaya. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Advances in therapy. vol 24. issue 1. 2007-06-22. PMID:17526456. |
improvement favoring clozapine+amisulpride could be attributed to the selective d2/d3 binding property of amisulpride, which had an additional effect in improving symptoms of schizophrenia. |
2007-06-22 |
2023-08-12 |
Not clear |
| A Hofer, M A Rettenbacher, M Edlinger, R Huber, T Bodner, G Kemmler, G Sachs, W W Fleischhacke. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. Pharmacopsychiatry. vol 40. issue 1. 2007-04-25. PMID:17327953. |
outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. |
2007-04-25 |
2023-08-12 |
Not clear |
| A Hofer, M A Rettenbacher, M Edlinger, R Huber, T Bodner, G Kemmler, G Sachs, W W Fleischhacke. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. Pharmacopsychiatry. vol 40. issue 1. 2007-04-25. PMID:17327953. |
we compared stable patients with schizophrenia who were treated with either amisulpride or olanzapine in terms of symptomatic outcome, neurocognitive functioning, functionality, and subjective outcome. |
2007-04-25 |
2023-08-12 |
Not clear |
| M Lambert, D Naber, F X Eich, M Schacht, M Linden, B G Schimmelman. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta psychiatrica Scandinavica. vol 115. issue 2. 2007-03-29. PMID:17244174. |
remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. |
2007-03-29 |
2023-08-12 |
Not clear |
| Maria A Rettenbacher, Christoph Ebenbichler, Alex Hofer, Georg Kemmler, Susanne Baumgartner, Monika Edlinger, Martina Hummer, Monika Lechleitner, W Wolfgang Fleischhacke. Early changes of plasma lipids during treatment with atypical antipsychotics. International clinical psychopharmacology. vol 21. issue 6. 2007-03-16. PMID:17012984. |
we conducted a prospective, open study in schizophrenia patients in order to compare body weight and serum lipids during treatment with amisulpride, ziprasidone, clozapine or olanzapine over a period of 4 weeks. |
2007-03-16 |
2023-08-12 |
Not clear |
| J-M Vanelle, S Douk. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. European psychiatry : the journal of the Association of European Psychiatrists. vol 21. issue 8. 2007-02-23. PMID:17113759. |
a double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. |
2007-02-23 |
2023-08-12 |
human |
| J-M Vanelle, S Douk. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. European psychiatry : the journal of the Association of European Psychiatrists. vol 21. issue 8. 2007-02-23. PMID:17113759. |
to compare the efficacy and safety of amisulpride and olanzapine in subjects with schizophrenia and comorbid depression in a randomised double-blind trial. |
2007-02-23 |
2023-08-12 |
human |
| Y Lecrubier, P Quintin, M Bouhassira, E Perrin, S Lancreno. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta psychiatrica Scandinavica. vol 114. issue 5. 2007-02-06. PMID:17022791. |
the treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. |
2007-02-06 |
2023-08-12 |
Not clear |
| Robert Göder, Josef Bernd Aldenhoff, Margret Boigs, Sisko Braun, Jakob Koch, Gunther Fritze. Delta power in sleep in relation to neuropsychological performance in healthy subjects and schizophrenia patients. The Journal of neuropsychiatry and clinical neurosciences. vol 18. issue 4. 2007-01-16. PMID:17135379. |
the authors analyzed delta power in sleep and neuropsychological performance in 16 patients with schizophrenia on stable medication with amisulpride and 17 healthy subjects. |
2007-01-16 |
2023-08-12 |
human |
| Stephen M Beard, Fiona Maciver, Johannes Clouth, Eckart Rüthe. A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. The European journal of health economics : HEPAC : health economics in prevention and care. vol 7. issue 3. 2007-01-09. PMID:16896764. |
second-generation atypical antipsychotics such as clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride and ariprazole offer the potential to reduce the significant health care resource demands in the treatment of schizophrenia through improved levels of initial clinical response and reduced levels of long-term acute relapse. |
2007-01-09 |
2023-08-12 |
Not clear |
| Jean-Pierre Olié, Edoardo Spina, Stephen Murray, Ruoyong Yan. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. International clinical psychopharmacology. vol 21. issue 3. 2006-10-24. PMID:16528136. |
ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. |
2006-10-24 |
2023-08-12 |
human |
| Jean-Pierre Olié, Edoardo Spina, Stephen Murray, Ruoyong Yan. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. International clinical psychopharmacology. vol 21. issue 3. 2006-10-24. PMID:16528136. |
we compared the efficacy of ziprasidone and amisulpride in the treatment of negative symptoms and overall psychopathology in subjects who had chronic schizophrenia with predominantly negative symptoms. |
2006-10-24 |
2023-08-12 |
human |